Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRx eyes new markets with appointment of Asian VP

"Jasmine's depth of experience in driving corporate IP strategies and business development, as well as bringing products to market in Asia, will be a huge asset to Volition," said CEO Cameron Reynolds.
Singapore
Dr Kway will be based in Volition’s office in Singapore

VolitionRx Limited (NYSEMKT:VNRX) signalled its intention to expand into Asian markets with the appointment of Dr Jasmine Kway as its vice president of Asia.

The decision to expand its footprint follows Tuesday’s news that it had achieved CE marking on its Nu.QTM Colorectal Cancer Screening Triage Test, paving the way for its expected launch across the European Union.

Volition plans to bring the product to market in Europe this year and now has its sights on Asia.

The company, which is developing blood-based diagnostic tests for different types of cancer, will be working with Dr Kway to expand into the Asian markets with direct marketing to countries with screening programs as well as seeking the required approvals for use in the new Asian markets.

Volition said Dr Kway has a proven track record in achieving positive business results by developing strategic business alliances, identifying new markets, and developing business processes.

To date she has worked with numerous health and regulatory bodies across Asia and has successfully introduced numerous private sector companies into the Asian markets.

Prior to joining Volition, Dr Kway was chief executive officer of intellectual property practice at RHT i-Assets Advisory, one of the leading companies of the RHT Group of Companies, and RHT Holdings (RHT), a Singapore-headquartered integrated leading professional services company providing professional services in Asia.

She will be based in Volition’s office in Singapore.

John-H.jpg
Why Invest In VolitionRx? Read More Here

Register here to be notified of future VNRX Company articles
View full VNRX profile

VolitionRx Timeline

Related Articles

Knee.jpg
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
Venn-Life.jpg
November 17 2016
It has been awarded what’s called CE-IVD certification, that’s the official CE mark for an in-vitro diagnostic medical device.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC